AQXP - Aquinox Pharmaceuticals, Inc.

Aquinox Pharmaceuticals, Inc. (AQXP) is a biopharmaceutical company that focuses on developing and commercializing novel therapies to treat inflammatory diseases. AQXP is headquartered in Vancouver, Canada, and was founded in 2003.

AQXP's lead product candidate is Rosiptor, a small molecule drug that targets SHIP1, a protein that plays a key role in regulating immune system function. AQXP is developing Rosiptor for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS) and other inflammatory diseases.

IC/BPS is a chronic bladder condition characterized by symptoms such as pelvic pain, urinary urgency, and frequency. There are currently no FDA-approved treatments for IC/BPS, and the condition is estimated to affect millions of people in the United States.

AQXP is also exploring the potential of Rosiptor in other inflammatory diseases, such as chronic obstructive pulmonary disease (COPD) and inflammatory bowel disease (IBD).

AQXP is a publicly traded company on the NASDAQ stock exchange, where its shares are listed under the ticker symbol AQXP.